Compare Mesoblast Limited (MESO) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Nucor Corporation — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Nucor Corporation trades at $248 (market cap $55.84B). The key difference: Nucor Corporation is far larger — about 31.9× Mesoblast Limited's market cap, and Nucor Corporation pays a 0.91% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Nucor Corporation for 78 Days on average.
| MESO | NUE | |
|---|---|---|
Market Cap | $1.75B | $55.84B |
Volume | 239,027 | 848,835 |
Sector | Health | Basic Materials |
52-Week High | $20.96 | $274.74 |
52-Week Low | $13.19 | $131.78 |
Typical Hold Time | 14 Days | 78 Days |
Enterprise Value | $1.83B | $60.25B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Nucor (NUE) trades at $246.44, down 1.84% on the day, with mixed technical signals showing neutral momentum. The stock has demonstrated strong earnings performance with recent beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Revenue has stabilized around $32.5B after declining from 2022 peaks, while profit margins show recovery signs. Analysts maintain a bullish stance with a $266.88 price target, representing 8% upside potential from current levels.
Nucor presents a balanced investment case with improving fundamentals but faces cyclical steel industry headwinds. The company's dividend king status and strong operational execution support long-term value, while competitive pressures and margin volatility remain key risks. Current valuation appears reasonable with P/E of 19.67 and P/S of 1.57, suggesting potential for moderate growth if steel demand strengthens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
